MAIA Biotechnology, Inc. Debt Conversion, Original Debt, Amount
MAIA Biotechnology, Inc. (MAIA) reported Debt Conversion, Original Debt, Amount of $240.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-24.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionOriginalDebtAmount1 · last filed 2023-03-24
- MAIA Biotechnology, Inc. debt conversion, original debt, amount for fiscal 2021 was $240.00K.
| Period end | Debt Conversion, Original Debt, Amount 12 month |
|---|---|
| 2021-12-31 | $240.00K 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |